Noticias de 0NZT.LSE | Roxom Stocks

1 BTC

=

- USD

Loading market data...

0N

Cap. mercado

$17.30B

Volumen

N/A

Próximos resultados

February 25th

Gráfico Finanzas Resultados Noticias Acerca de Dividendos Insiders Reportes

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 202524 scientific abstracts reflect UCB's ongoing commitment to improving outcomes for people living with neurological conditions, including rare epilepsies Dravet syndrome and Lennox-Gastaut syndrome, as well as generalized myasthenia gravis and thymidine kinase 2 deficiency. Resear…finance.yahoo.com · Apr 3, 2025

UCB Convening Notice to the General Meeting of the Shareholders 2025UCB CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 24 April 2025, at 11:00 am CEST, at the registered office of UCB…finance.yahoo.com · Mar 21, 2025

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 ConferenceClinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and doxribtimine (dT) - an investigational pyrimidine nucleoside therapy - in people living with thymidine kinase 2 deficiency (TK2d).1,2,3 Additi…finance.yahoo.com · Mar 19, 2025

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet SyndromeFINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age and older1 Results showed the most common treatment-emergent adverse events were p…finance.yahoo.com · Mar 12, 2025

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease BurdenOver half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment.≠ DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflamm…finance.yahoo.com · Mar 7, 2025

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque PsoriasisSustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with BIMZELX® (bimekizumab-bkzx) achieved PASI100+ at five years Durable and broad effic…finance.yahoo.com · Mar 7, 2025

On Growth Path for a Decade plus: Strong Launch Execution driving Company GrowthRevenue in 2024 increased to € 6.15 billion, a plus of 17% (+19% CER1), Net sales were up by 15% to € 5.61 billion (+17% CER1) driven by a strong, triple- and double-digit growth performance of newly launched growth drivers: BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO® and ZILBRYSQ® …finance.yahoo.com · Feb 27, 2025

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)BIMZELX® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection device offers convenience for patients requiring a 320 mg dose of BIMZELX with singl…finance.yahoo.com · Jan 16, 2025

Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage StudyAn experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition. Continue reading View commentsfinance.yahoo.com · Dec 19, 2024

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific SessionUCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular research Presentations showcase new data for UCB's gMG treatments, including post hoc analyses highlighting t…finance.yahoo.com · Oct 11, 2024

0N

0NZT.LSEUCB SA

0NZT.LSE

Pagar con—

Empezar a operar

Saldo disponible0,00

Tu posiciónAún no tienes 0NZT.LSE.

Tickers relacionados

Resultados

Dividendos

Último · May 1

Importe$1.02

Rendimiento49.52%

Anual$1.02